Pelacarsen is an antisense therapy that is designed to reduce Lipoprotein(a) concentrations in people with high levels of the lipoprotein and who are at risk of cardiovascular disease.[1][2][3] It is developed by Ionis and Novartis.[4]

References

  1. ↑ Yeang, Calvin; Karwatowska-Prokopczuk, Ewa; Su, Fei; Dinh, Brian; Xia, Shuting; Witztum, Joseph L.; Tsimikas, Sotirios (March 2022). "Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol". Journal of the American College of Cardiology. 79 (11): 1035–1046. doi:10.1016/j.jacc.2021.12.032.
  2. ↑ Karwatowska‑Prokopczuk, Ewa; Lesogor, Anastasia; Yan, Jing-He; Hurh, Eunju; Hoenlinger, Angelika; Margolskee, Alison; Xia, Shuting; Tsimikas, Sotirios (January 2023). "Efficacy and safety of pelacarsen in lowering Lp(a) in healthy Japanese subjects". Journal of Clinical Lipidology. 17 (1): 181–188. doi:10.1016/j.jacl.2022.12.001.
  3. ↑ Fernandez-Prado, Raul; Perez-Gomez, Maria Vanessa; Ortiz, Alberto (1 October 2020). "Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease". Clinical Kidney Journal. 13 (5): 753–757. doi:10.1093/ckj/sfaa001. PMC 7577764.
  4. ↑ Dharma, RanjithKumar (4 August 2023). "Ionis, Novartis to develop medicine for cardiovascular disease". Pharmaceutical Technology. Retrieved 23 November 2023.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.